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ABSTRACT
Background: Heterozygous loss-of-function muta-
tions in the acid beta-glucocerebrosidase (GBA1)
gene, responsible for the recessive lysosomal stor-
age disorder, Gaucher’s disease (GD), are the strong-
est known risk factor for Parkinson’s disease (PD).
Our aim was to assess the contribution of GBA1
mutations in a series of early-onset PD. Methods:
One hundred and eighty-five PD patients (with an onset
age of 50) and 283 age-matched controls were
screened for GBA1 mutations by Sanger sequencing.
Results: We show that the frequency of GBA1 muta-
tions is much higher in this patient series than in typi-
cal late-onset patient cohorts. Furthermore, our
results reveal that the most prevalent PD-associated
GBA1 mutation is E326K, a variant that does not,
when homozygous, cause GD. Conclusions: Our
results confirm recent reports that the mutation,
E326K, predisposes to PD and suggest that, in addi-
tion to reduced GBA1 activity, other molecular mecha-
nisms may contribute to the development of the
disease. VC 2012 Movement Disorder Society
Key Words: GBA; E326K; Parkinson’s disease;
Gaucher’s disease; early onset
A large number of Mendelian genetic loci have been
described for Parkinson’s diseases (PD;
OMIM#168600)1 and genome wide association studies
(GWAS) have also identified many common, low-risk
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variants.2 However, the most prevalent genetic risk fac-
tor identified to date is heterozygous loss-of-function
variants in the acid beta-glucocerebrosidase gene
(GBA1).3 Homozygous or compound heterozygous
loss-of-function mutations in GBA1 cause Gaucher’s
disease (GD) (OMIM 606463), a recessive lysosomal
storage disorder with multisystem involvement.4
The association between PD and GBA1 was first
identified through the observation of parkinsonism
and Lewy body (LB) pathology among GD cases and
their first- and second-degree relatives.5
So far, genetic analysis has suggested that all patho-
genic GBA1 mutations, causing GD, can equally pre-
dispose to PD. Therefore, the assumption has been
that variants that, when homozygous, did not lead to
GD would not predispose to PD.3
We have embarked on a systematic analysis of the
relationship between GD, PD, and other LB disorders
and the GBA1 gene.6–8 As part of this study, we per-
formed a complete sequence analysis of the open read-
ing frame (ORF) of the gene by Sanger sequencing in
a cohort of 185 PD cases with an age at onset of 50
years. We compared these data with those obtained
from 283 controls (these latter overlapped with our
recent report6) and with a similar analysis of 73
patients with type 1 GD from the same geographic
region.9
Patients and Methods
Subjects
The PD patients were a group of 185 unrelated indi-
viduals with an onset age of 50 years who came in
to the movement disorders clinics at the National
Hospital for Neorology and Neurosurgery (London,
UK). They all met the UK Brain Bank Clinical Criteria
for PD.10 Average age at onset was 40 6 7.2 years
(range, 16–50).
A total of 27.5% of patients (51 of 185) reported a
family history compatible with PD in at least a first-
or second-degree relative. All the patients in this series
were previously screened for mutations in parkin and
genotyped for the common LRRK2 mutation,
G2019S.
Controls were age-matched subjects. This series of
controls has been previously reported,6 with the addi-
tion of 26 age-matched spouse controls. Controls were
examined and interviewed by experienced neurologists
to rule out signs and symptoms suggestive of PD. All
controls were of UK Caucasian origin, and no individ-
ual reported an Ashkenazi background.
GD patients were 73 unrelated subjects, affected
with the type 1 form of the disease (non-neurono-
pathic), attending the national GD clinics at the Royal
Free and Addenbrookes hospitals. 16 were Ashkenazi
Jewish (22%) and 4 had Eastern European ancestry
(5.7%); the remainder were white UK citizens without
Ashkenazi ancestry.
Written informed consent was taken from each par-
ticipant; this study was approved by the North West
London and Cambridge University hospitals ethics
committees.
DNA Sequencing
The ORF (11 exons) of the GBA1 gene was entirely
sequenced in cases and controls, as we have previously
described.6,7 The sequence reference and exon num-
bering were those of GenBank accession number
NM_000157.3.
Results
The results of this analysis are summarized in
Tables 1 and 2.
They are surprising in two ways. The first is that,
in this population of early-onset PD, a very high pro-
portion of cases carried a GBA1 variant (25.94%; 48
of 185 individuals; odds ratio [OR] for carriers of
any variant in cases versus controls: 7.9; 95% confi-
dence interval [CI]: 4.1–15.4; P < 0.0001).
Among those, 22 cases had a known GD-causing
pathogenic mutation (19 with one mutation and 3
with two mutations), a proportion far higher than in
late-onset PD from the same population we have
recently reported (11.9%; 22 of 185 individuals ver-
sus 3.8%; 30 of 790; P ¼ 0.0001).6 Notably, 2 PD
patients were homozygous, respectively, for N370S
and R463C, and despite both genotypes being
known to cause GD, they did not display any GD
features.
Nevertheless, the clinical spectrum in GD is wide,
and some studies suggest that patients homozygous for
mild mutations, such as N370S or R463C, may never
develop the disease.11,12 Moreover, subjects with two
pathogenic GBA1 mutations, affected with typical PD
but showing no signs of GD, have already been
described.13
The second surprising discovery is that, by far, the
most common variant in the PD cases was E326K,
which had a frequency of 7.57% in cases (14 of
185 individuals; 12 cases were heterozygote, includ-
ing 1 in combination with L444P and 2 homozy-
gote) and 2.47% in controls (7 of 283 individuals).
To further confirm this observation, an additional
202 controls were screened for just this variant and
the frequency in these samples was 2.97% (6 of
202). The total frequency in controls, taking into
account both sets, was 2.68% (13 of 485 individu-
als), indicating a significant association of this vari-
ant with PD (P ¼ 0.0059; OR, 2.97; 95% CI: 1.3–
6.4). In contrast, this variant did not occur in the
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GD cohort from the same population,9 consistent
with previous reports that this variant does not seg-
regate with GD.14
Indeed, the 2 PD cases homozygous for the E326K
variant did not have any of the clinical or hematologi-
cal features of GD, and their white blood cell GBA1
enzymatic activity was at the lower limit of normal
range.
It should be noted that we found other variants in
our PD series that have not been found in GD cases
and that, collectively, these were more common in
cases than in controls. Although further population
studies and functional analyses are needed, our results
suggest that there may be other mutations that predis-
pose to PD, but are not associated with GD (Table 1).
The possible effect of these variants on protein func-
tion was evaluated by in silico prediction tools (Sup-
porting Materials).
Among the PD carriers of the E326K, all of which
were British with no reported Ashkenazi Jewish ori-
gin, none had parkin mutations, whereas 1 carried
also the common LRRK2 mutation, G2019S. This
patient developed PD symptoms when he was 35,
much earlier than the average age at onset of the
LRRK2 mutation carriers,15 hinting at a possible syn-
ergistic effect of the two variants on the onset
anticipation.
Discussion
Herein, we report the largest series of early-onset
PD cases in which GBA1 was entirely sequenced, and
we show that the frequency of GBA1 mutations is
much higher than in late-onset patients from the same
geographic area. Interestingly, the GBA1 variant,
E326K, is, by far, the most common variant found in
this cohort.
The possibility that the E326K may be associated
with PD has been raised before, but dismissed,
because in previous studies, it was considered a be-
nign polymorphic variant and the association with
PD was not as strong as we report in this study.13,16
Our results put this uncertainty beyond doubt and
show that indeed this variant does predispose to PD.
Consistent with this finding, a similar result was
recently published by Pankratz et al. as part of a
large meta-analysis of the existing available PD
GWAS datasets, in which the E326K reached ge-
nome-wide significance (OR, 1.71; P ¼ 5  108)
and hence was indicated as a susceptibility allele for
PD.17
These positive results are in contrast with the large
multicenter analysis of GBA1 in PD from Sidransky
et al., which did not show this association.3 This dis-
crepancy could be explained by the heterogeneity of
populations included in that study, because it was
enriched with individuals from populations (Asian,
Jewish, and Portuguese) in which the E326K is absent
or very rare.18–20
Although biochemical observations have suggested
that the E326K is a subtle loss-of-function variant,21,22
this reduction of the activity is clearly not severe
enough to lead to disease in the tissues where GD is
associated with lysosomal storage dysfunction. Never-
theless, when E326K is found in the same allele with
another mutant variant, such as L444P, N188S, or
Table 1. Proportion of cases and controls with GBA mutations and OR
GBA Variants
% in PD
Cases (n ¼ 185)
% in Controls
(n ¼ 283)
% in Type 1 GD
Cases (n ¼ 73) OR (95% CI)
All GBA variants 25.94 (48) 4.24 (12) 100 (73)f 7.9 (4.1–15.4)
All pathogenic GBA variants 20 (37) 3.18 (9) 100 (73) 7.6 (3.57–16.20)
N370S 2.70 (5) 0.35 (1) 86.30 (63) 7.8 (0.9–67.6)
L444P 1.08 (2) 0 (0) 24.66 (18) Ø
RecNciI (L444PþA456PþV460V) 1.6 (3) 0 (0) 10.96 (8) Ø
R463C 1.62 (3) 0 (0) 5.48 (4) Ø
E326K 7.57 (14) 2.47 (7)a 0 (0) 3.2 (1.2–8.1)
Other pathogenic mutations 5.4 (10)b 0.35 (1)c 45.2 (33) 16.1 (2.04–126.97)
Other variants with unproven pathogenicity 7.03 (13)d 1.06 (3)e 0 (0) 7.0 (1.9–25.1)
Allele names refer to the processed protein, excluding the 39-residue signal peptide. The number of carriers for each GBA variant is in brackets. Ø means that
OR cannot be calculated because all carriers were cases (divide by zero).
aAdditionally, a further 202 individuals were screened for just this variant and the frequency in these additional samples was 2.97% (6 of 202). The total
frequency, taking into account both sets of controls, was 2.68% (13 of 485 individuals). Furthermore, the frequency in Caucasians of this variant, as reported
by the Exome Variant Server database (http://evs.gs.washington.edu/EVS/), is 2.36% (82 of 3,469 individuals).
bIVS2þ1 (1), R131C (2), W184R (1), N188S (1), H255Q (1), R257Q (1), D409H (2), and RecTL (1).
cR257Q (1).
dE388K (1), G113A (2), T369M (1), and S465P (1) have been previously reported in both cases and controls; L(14)V (1), V172L (2), S177T (1), L217P (1),
L317L (1), L354P (1), V375G (1), IVS10-4 C>T(1), and IVS10-12 C>T (1) and are novel variants.
eE340A (1), T369M (1), and V458L (1).
fIn 2 patients, a second mutation could not be identified. Both showed a clear enzymatic deficiency and a clinical diagnosis fully consistent with type 1 GD.
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N370S, it does not act as a neutral allele and instead
contributes to GD severity by further reducing the re-
sidual enzymatic activity.23–26
We propose that the association of the E326K with
PD and its absence in the GD cohort, together with
the presence of many other novel, rare GBA1 var-
iants in the PD group, which are not associated with
GD, might suggest a dissociation of the pathogenic
molecular mechanisms that underlie these two
diseases.
However, it is not clear whether the mild loss of
function of the allele, E326K, is the cause of the
increased risk for PD or whether other, still unknown,
effects of the mutation on the lysosomal machinery
Table 2. Genetic, demographic, and clinical information of patients with GBA variants
Patient Gender Genotype
Age at
Onset
Familial
History Parkin LRRK2
1 M R463C/wt 45 Yes – –
2 M N370S/wt 46 Yes – –
3 F E326K, L444Pa 34 No – –
4 F E326K/wt 36 NA – –
5 F R257Q/wt 42 No – –
6 F RecTL/wt 44 No – –
7 M E388K/wt 37 NA – –
8 M E326K/E326K 42 Yes – –
9 M RecNcil/wt 41 No – –
10 F D409H/wt 40 No – –
11 F T369M, IVS10 12 C>Ta 39 NA p.P437L/wt –
12 M E326K/E326K 38 Yes – –
13 F IVS2þ1 G>A/wt 42 No – –
14 M R463C/R463C 45 Yes – –
15 M L217P/wt 42 No – –
16 F N188S/wt 49 NA – –
17 M IVS10 4C>T/wt 29 No Deletion of exons
4,5, and 6
–
18 M E326K/wt 50 Yes – –
19 M L444P/wt 49 No – –
20 M E326K/wt 35 No – p.G2019S/wt
21 M N370S/wt 48 Yes – p.G2019S/wt
22 F E326K/wt 44 No – –
23 F E326K/wt 49 Yes – –
24 F E326K/wt 44 No – –
25 F G113A/wt 37 Yes – –
26 M S465P/wt 45 No – –
27 M E326K/wt 42 Yes – –
28 F V375G/wt 50 No – –
29 M R463C/wt 42 NA – –
30 F RecNcil/wt 31 NA p.P437L/wt –
31 F L354P/wt 38 NA – –
32 F L317L/wt 40 NA – –
33 M RecNcil/wt 39 NA – –
34 M S177T, V172La 38 Yes – –
35 M E326K/wt 21 NA – –
37 M L(-14)V/wt 30 No – –
38 F V172L/wt 45 Yes – –
39 M N370S/N370S 48 No – –
40 F H255Q, D409Ha 38 Yes – –
41 F R131C/wt 43 No – –
42 M W184R/wt 36 Yes p.Pro113fs/p.Gly430Asp –
43 M E326K/wt 40 No – –
44 M E326K/wt 45 No – –
45 M N370S/wt 35 No – –
46 M R131C/wt 50 NA – –
47 F E326K/wt 29 No – –
48 M N370S/wt 27 NA c.535-9T>A –
Age at onset is expressed in years. Dashes represent negative. Patients 14 and 39 did not have GD symptoms.
aUnknown phase.
Abbreviations: M, male; F, female; NA, data not available; ND, not done; wt, wild type.
G B A E 3 2 6 K P R E D I S P O S E S T O P D
Movement Disorders, Vol. 28, No. 2, 2013 235
are contributing to neuron degeneration. Recent stud-
ies from our laboratories suggest that heterozygous
GBA1 mutations may accelerate the pathogenesis of
PD through a gain-of-function effect that may include
endoplasmic reticular stress.27
We propose to investigate the molecular mechanisms
potentially involved in the pathogenesis of PD of this
interesting GBA mutation in cultured skin fibroblasts
derived from patients. We suggest it could be a suita-
ble cell model to characterize the molecular bases of
GBA contribution to PD.
Conclusion
In conclusion, our study strong links the allele
E326K with early-onset PD in a sample of UK individ-
uals and reflects the need to accurately explore the
contribution of this and other GBA rare variants to
the increased risk of PD.
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